Posted: Thu Jun 04, 2009 9:55 pm Post subject: NIH to Evaluate Novavax's VLP Candidate for H1N1 Strain
The company produced the first batch of H1N1 VLPs in its laboratories in May, three weeks after the CDC announced the genetic sequence of the novel H1N1 virus, which was isolated from an infected person located in California. Novavax' VLPs contain hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins, which were found in this strain.
The size and structure of the VLPs are nearly identical to those of the novel H1N1 virus, but the VLPs are not infectious, as they lack the genes necessary for replication, the company explains. Novavax has made purified influenza A VLPs, which are being sent to scientists at the CDC and DMID for studies in animal models. Novavax has also completed genetic engineering and manufacture of the master seed stock necessary to produce larger quantities of the investigational H1N1 VLP vaccine under cGMP conditions in its manufacturing facility in Rockville, MD.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum